Log In
BCIQ
Print this Print this
 

EVT100 series (formerly ENS 103, EVT 100 series, EVT 103)

  Manage Alerts
Collapse Summary General Information
Company Evotec AG
DescriptionNMDA receptor NR2B subtype (GRIN2B; NR2B) antagonist
Molecular Target NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationDepression
Indication DetailsTreat treatment-resistant depression
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$310.0M

$10.0M

$235.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/16/2009

$310.0M

$10.0M

$235.0M

Get a free BioCentury trial today